药物基因组学在致幻剂辅助治疗临床研究中的应用
本综述汇总了药物基因组学在致幻剂辅助治疗中的潜在应用,涵盖LSD、裸盖菇素、DMT、5-MeO-DMT、伊博格碱和MDMA。现有药代动力学证据提示CYP450等药物代谢酶基因变异可影响LSD和伊博格碱急性效应强度,CYP2D6慢代谢者可能需要减量。作者建议在临床研究中进一步评估药物基因组学检测的价值。
要点
- CYP450酶基因变异可能影响LSD和伊博格碱的急性致幻效应强度
- CYP2D6慢代谢者使用LSD和伊博格碱时可能需要减量
- 药物基因组学检测在致幻剂治疗中的价值尚需临床研究进一步验证
核心结论
- 早期证据提示遗传因素可影响某些致幻剂的效果,建议在临床研究中进一步评估药物基因组学检测。
- 药物基因组学检测有望改善致幻剂治疗的安全性和治疗特征,并可能在未来用于个体化治疗。
研究设计与样本
- 综述类文章,汇总文献并探讨遗传变异对多种致幻剂药效学和药代动力学的潜在影响。
- 涉及的致幻剂包括LSD、裸盖菇素、DMT、5-MeO-DMT、伊博格碱和MDMA。
主要发现
- 药代动力学研究表明,细胞色素P450等药物代谢酶的遗传变异可影响LSD和伊博格碱急性致幻效应的强度。
- CYP2D6慢代谢者使用LSD和伊博格碱时可能需要减量。
- 基于临床前证据推测,当与单胺氧化酶抑制剂联用时,CYP2D6代谢者状态可能影响5-MeO-DMT和裸盖菇素的急性致幻体验。
- 现有证据有限,尤其是在药效学方面。
关键数值与推荐
- CYP2D6慢代谢者使用LSD和伊博格碱时可能需要减量。
- CYP2D6代谢者状态可能影响5-MeO-DMT和裸盖菇素与单胺氧化酶抑制剂联用时的急性致幻体验(基于临床前证据的推测)。
临床怎么用
- 临床实践中可关注CYP2D6代谢者状态,对慢代谢者考虑LSD和伊博格碱减量。
- 致幻剂与单胺氧化酶抑制剂联用时,应关注CYP2D6代谢者状态对5-MeO-DMT和裸盖菇素效应的潜在影响。
- 药物基因组学检测在致幻剂辅助治疗中的应用尚处于研究阶段,需进一步临床验证。
局限性
- 现有证据有限,尤其是药效学方面的证据。
- 关于5-MeO-DMT和裸盖菇素与单胺氧化酶抑制剂联用的推测基于临床前证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psychedelics have recently re-emerged as potential treatments for various psychiatric conditions that impose major public health costs and for which current treatment options have limited efficacy. At the same time, personalized medicine is increasingly being implemented in psychiatry to provide individualized drug dosing recommendations based on genetics. This review brings together these topics to explore the utility of pharmacogenomics (a key component of personalized medicine) in psychedelic-assisted therapies. We summarized the literature and explored the potential implications of genetic variability on the pharmacodynamics and pharmacokinetics of psychedelic drugs including lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), ibogaine and 3,4-methylenedioxymethamphetamine (MDMA). Although existing evidence is limited, particularly concerning pharmacodynamics, studies investigating pharmacokinetics indicate that genetic variants in drug-metabolizing enzymes, such as cytochrome P450, impact the intensity of acute psychedelic effects for LSD and ibogaine, and that a dose reduction for CYP2D6 poor metabolizers may be appropriate. Furthermore, based on the preclinical evidence, it can be hypothesized that CYP2D6 metabolizer status might contribute to altered acute psychedelic experiences with 5-MeO-DMT and psilocybin when combined with monoamine oxidase inhibitors. In conclusion, considering early evidence that genetic factors can influence the effects of certain psychedelics, we suggest that pharmacogenomic testing should be further investigated in clinical research. This is necessary to evaluate its utility in improving the safety and therapeutic profile of psychedelic therapies and a potential future role in personalizing psychedelic-assisted therapies, should these treatments become available.
引用
- Halman A, Conyers R, Moore C, et al. Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy. Clin Pharmacol Ther. 2024. PMID: 39345195. doi:10.1002/cpt.3459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。